Amneal Pharmaceuticals/AMRX

$5.40

-1.28%
-
1D1W1MYTD1YMAX

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc., is a fully integrated global essential medicine company. The Company is engaged in the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. The Company’s Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermal across a broad range of therapeutic categories. The Company's Specialty segment’s portfolio includes central nervous system disorders (Parkinson’s disease, spasticity, migraine), endocrinology (hypothyroidism), and other therapeutic areas. The Company’s AvKARE segment provides pharmaceuticals, medical and surgical products, and services to government, retail, and institutional markets.

Ticker

AMRX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

J. Kevin Buchi

Employees

7,600

Headquarters

Bridgewater, United States
Website
amneal.com

AMRX Metrics

BasicAdvanced
$1.68B
Market cap
86.37
P/E ratio
$0.06
EPS
1.32
Beta
-
Dividend rate

What the Analysts think about AMRX

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 5 analysts.
26.85% upside
High $8.00
Low $6.00
$5.40
Current price
$6.85
Average price target

AMRX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
1.54% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$620M
3.51%
Net income
$9.6M
-19.33%
Profit margin
1.54%
-22.22%

AMRX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 55.21%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.12
$0.19
$0.19
$0.14
-
Expected
$0.10
$0.11
$0.13
$0.09
$0.10
Surprise
25%
79.25%
49.84%
55.21%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Amneal Pharmaceuticals stock

Buy or sell Amneal Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing